반응식
N1(O[C:11]2[N:16]=[C:15]([NH:17][C:18]3[CH:26]=[CH:25][CH:24]=[C:23]4[C:19]=3[CH:20]=[CH:21][N:22]4[CH3:27])[C:14]([C:28]([NH2:30])=[O:29])=[CH:13][N:12]=2)C2C=CC=CC=2N=N1.[N:31]1([CH2:36][CH2:37][O:38][C:39]2[CH:45]=[CH:44][C:42]([NH2:43])=[CH:41][CH:40]=2)[CH2:35][CH2:34][CH2:33][CH2:32]1.O.C1(C)C=CC(S(O)(=O)=O)=CC=1>CN1C(=O)CCC1>[CH3:27][N:22]1[C:23]2[C:19](=[C:18]([NH:17][C:15]3[C:14]([C:28]([NH2:30])=[O:29])=[CH:13][N:12]=[C:11]([NH:43][C:42]4[CH:44]=[CH:45][C:39]([O:38][CH2:37][CH2:36][N:31]5[CH2:35][CH2:34][CH2:33][CH2:32]5)=[CH:40][CH:41]=4)[N:16]=3)[CH:26]=[CH:25][CH:24]=2)[CH:20]=[CH:21]1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
반응 조건
- 온도
- 100 °C
실험 절차
To a solution of 2-(1H-benzo[d][1,2,3]triazol-1-yloxy)-4-(1-methyl-1H-indol-4-ylamino)pyrimidine-5-carboxamide (62 mg, 0.15 mmol) in NMP (1 ml) was added 4-(2-(pyrrolidin-1-yl)ethoxy)aniline (31 mg, 0.15 mmol) and p-toluenesulfonic acid hydrate (28 mg, 0.15 mmol). It was heated at 100° C. for 4 h, and was purified by preparative HPLC to give 4-(1-methyl-1H-indol-4-ylamino)-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidine-5-carboxamide (32 mg). MS found for C26H29N7O2 as (M+H)+ 472.4. UV: λ=216.9, 257.0.
후처리
- customwas purified by preparative HPLC
출처 및 근거
- ORD 기록
- ord-5b70ef8a7d3746bab0a9cc273c1c6e4d
- 출처 데이터셋
- uspto-grants-2013_08
- 특허 번호
- US08501944B2
연결된 노트
불러오는 중…